DK1401801T3 - Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf - Google Patents

Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf

Info

Publication number: DK1401801T3
Authority: DK; Denmark
Prior art keywords: androgen receptor; administration; selective androgen; receptor modulator; alkyl
Prior art date: 2000-08-24

Application number

DK01964368T

Other languages

Danish (da)

English (en)

Inventor

Duane D Miller

Yali He

James Dalton

Donghua Yin

Original Assignee

Univ Tennessee Res Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-24

Filing date

2001-08-23

Publication date

2007-03-05

2001-08-23 Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation

2007-03-05 Application granted granted Critical

2007-03-05 Publication of DK1401801T3 publication Critical patent/DK1401801T3/da

Links

238000000034 method Methods 0.000 title abstract 5
239000000849 selective androgen receptor modulator Substances 0.000 title abstract 5
229940083324 Selective androgen receptor modulator Drugs 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 3
125000001475 halogen functional group Chemical group 0.000 abstract 2
QLNJFJADRCOGBJ-LBPDFUHNSA-N propanamide Chemical class CC[13C](N)=O QLNJFJADRCOGBJ-LBPDFUHNSA-N 0.000 abstract 2
101100149678 Caenorhabditis elegans snr-3 gene Proteins 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
102000001307 androgen receptors Human genes 0.000 abstract 1
108010080146 androgen receptors Proteins 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
238000001794 hormone therapy Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
230000021595 spermatogenesis Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)

DK01964368T 2000-08-24 2001-08-23 Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf DK1401801T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64497000A	2000-08-24	2000-08-24
US30008301P	2001-06-25	2001-06-25
PCT/US2001/026328 WO2002016310A1 (fr)	2000-08-24	2001-08-23	Modulateurs selectifs du recepteur androgenique et procedes d'utilisation de ces derniers

Publications (1)

Publication Number	Publication Date
DK1401801T3 true DK1401801T3 (da)	2007-03-05

Family

ID=26971579

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01964368T DK1401801T3 (da)	2000-08-24	2001-08-23	Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf
DK04019299T DK1491524T3 (da)	2000-08-24	2001-08-23	Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK04019299T DK1491524T3 (da)	2000-08-24	2001-08-23	Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf

Country Status (20)

Country	Link
US (1)	US6569896B2 (fr)
EP (4)	EP2284149A1 (fr)
JP (2)	JP2004518617A (fr)
KR (1)	KR20030061783A (fr)
CN (2)	CN1736371B (fr)
AT (2)	ATE344233T1 (fr)
AU (2)	AU8523001A (fr)
BR (1)	BR0114801A (fr)
CA (1)	CA2420279C (fr)
CY (2)	CY1105956T1 (fr)
DE (2)	DE60137728D1 (fr)
DK (2)	DK1401801T3 (fr)
EA (2)	EA007101B1 (fr)
ES (2)	ES2321933T3 (fr)
GE (1)	GEP20053586B (fr)
HR (1)	HRP20030118B1 (fr)
MX (1)	MXPA03001632A (fr)
PT (2)	PT1401801E (fr)
SI (1)	SI1401801T1 (fr)
WO (1)	WO2002016310A1 (fr)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050038110A1 (en) *	2000-08-24	2005-02-17	Steiner Mitchell S.	Selective androgen receptor modulators and methods of use thereof
US6071957A (en) *	1996-11-27	2000-06-06	The University Of Tennessee Research Corporation	Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6995284B2 (en)	2000-08-24	2006-02-07	The University Of Tennessee Research Foundation	Synthesis of selective androgen receptor modulators
US7518013B2 (en)	2000-08-24	2009-04-14	University Of Tennessee Research Foundation	Selective androgen receptor modulators
US7759520B2 (en)	1996-11-27	2010-07-20	University Of Tennessee Research Foundation	Synthesis of selective androgen receptor modulators
US20040176470A1 (en) *	1998-05-07	2004-09-09	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) *	1998-05-07	2004-05-13	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US6566372B1 (en) *	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1411373A (zh) *	1999-12-16	2003-04-16	特瓦制药工业有限公司	制备来氟米特的新方法和新晶形的来氟米特
MXPA02012605A (es)	2000-06-28	2003-05-14	Squibb Bristol Myers Co	Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
US20040260108A1 (en) *	2001-06-25	2004-12-23	Dalton James T.	Metabolites of selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) *	2000-08-24	2005-01-04	University Of Tennessee Research Foundation	Formulations comprising selective androgen receptor modulators
US20070173546A1 (en) *	2000-08-24	2007-07-26	Dalton James T	Selective androgen receptor modulators and method of use thereof
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en)	2000-08-24	2006-02-14	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) *	2001-12-06	2011-08-30	University Of Tennessee Research Foundation	Treating muscle wasting with selective androgen receptor modulators
US8445534B2 (en)	2000-08-24	2013-05-21	University Of Tennessee Research Foundation	Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7919647B2 (en) *	2000-08-24	2011-04-05	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en)	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
US7855229B2 (en)	2000-08-24	2010-12-21	University Of Tennessee Research Foundation	Treating wasting disorders with selective androgen receptor modulators
US7645898B2 (en)	2000-08-24	2010-01-12	University Of Tennessee Research Foundation	Selective androgen receptor modulators and method of use thereof
US7026484B2 (en) *	2001-02-23	2006-04-11	Ligand Pharmaceuticals Incorporated	Tricyclic androgen receptor modulator compounds and methods
US20060004042A1 (en) *	2001-08-23	2006-01-05	Dalton James T	Formulations comprising selective androgen receptor modulators
US20080249183A1 (en) *	2001-11-29	2008-10-09	Steiner Mitchell S	Treatment of androgen-deprivation induced osteoporosis
US20070161608A1 (en) *	2001-12-06	2007-07-12	Dalton James T	Selective androgen receptor modulators for treating muscle wasting
DK1463497T3 (da) *	2001-12-06	2012-01-30	Gtx Inc	Behandling af muskelsvind med selektive androgenreceptormodulatorer
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
CA2475108A1 (fr) *	2002-02-07	2003-08-14	Mitchell S. Steiner	Traitement de l'hyperplasie prostatique benigne a l'aide de modulateurs selectifs des recepteurs androgenes (sarm)
US7772433B2 (en) *	2002-02-28	2010-08-10	University Of Tennessee Research Foundation	SARMS and method of use thereof
US7803970B2 (en)	2002-02-28	2010-09-28	University Of Tennessee Research Foundation	Multi-substitued selective androgen receptor modulators and methods of use thereof
HRP20040818A2 (en) *	2002-02-28	2005-02-28	University Of Tennessee Research Foundation	Haloacetamide and azide substituted compounds and methods of use thereof
US7705182B2 (en) *	2002-02-28	2010-04-27	University Of Tennessee Research Foundation	Multi-substituted selective androgen receptor modulators and methods of use thereof
AU2003216153B2 (en) *	2002-02-28	2008-01-24	The University Of Tennessee Research Foundation	Multi-substitued selective androgen receptor modulators and methods of use thereof
KR20040104463A (ko) *	2002-02-28	2004-12-10	유니버시티 오브 테네시 리서치 파운데이션	비가역적 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법
AU2003217304A1 (en) *	2002-02-28	2003-09-16	The University Of Tennessee Research Corporation	Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
EP2266577B8 (fr) *	2002-02-28	2015-01-21	University Of Tennessee Research Foundation	Modulateurs de récepteur sélectif d'androgène à substitutions multiples et procédé d'utilisation associés
US7741371B2 (en) *	2002-06-17	2010-06-22	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
JP2005529952A (ja) *	2002-06-17	2005-10-06	ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション	Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法
EP1562906A4 (fr) *	2002-10-15	2009-12-02	Univ Tennessee Res Foundation	Modulateurs heterocycliques selectifs du recepteur des androgenes et procedes d'utilisation associes
CA2502209A1 (fr) *	2002-10-15	2004-04-29	University Of Tennessee Research Foundation	Modulateurs selectifs du recepteur des androgenes a liaison methylene et procedes d'utilisation associes
US20060276539A1 (en) *	2002-10-16	2006-12-07	Dalton James T	Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (fr) *	2002-10-16	2004-04-29	Gtx, Inc.	Traitement d'etats associes au deficit androgenique lie a l'age chez l'homme (adam) au moyen de composes sarm
US20040087810A1 (en) *	2002-10-23	2004-05-06	Dalton James T.	Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en)	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
JP4603528B2 (ja) *	2003-01-13	2010-12-22	ジーティーエックス・インコーポレイテッド	選択的アンドロゲン受容体の大規模合成
AU2004206909A1 (en) *	2003-01-22	2004-08-05	Gtx Inc.	Treating androgen deficiency in female (ADIF)-associated conditions with sarms
US20040167103A1 (en) *	2003-02-24	2004-08-26	Dalton James T.	Haloacetamide and azide substituted compounds and methods of use thereof
CN1835937B (zh) *	2003-06-13	2012-07-18	詹森药业有限公司	作为选择性雄激素受体调节剂(sarms)的噻唑啉衍生物
KR20060035629A (ko) *	2003-06-27	2006-04-26	오리온 코포레이션	안드로젠 수용체 모듈레이터로 유용한 프로피온아마이드유도체들
CN100462353C (zh) *	2003-06-27	2009-02-18	奥赖恩公司	用作雄激素受体调节剂的丙酰胺衍生物
FI20030958A0 (fi) *	2003-06-27	2003-06-27	Orion Corp	Uusia yhdisteitä
MXPA06001751A (es)	2003-08-22	2006-05-12	Ligand Pharm Inc	Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
WO2005037201A2 (fr) *	2003-10-14	2005-04-28	Gtx, Inc.	Traitement des troubles osseux avec des modulateurs de recepteurs d'androgenes selectifs
GB0324551D0 (en) *	2003-10-21	2003-11-26	Karobio Ab	Novel compounds
US7202234B2 (en) *	2003-10-24	2007-04-10	Eisai Co., Ltd.	Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
CN1882327A (zh)	2003-11-19	2006-12-20	症变治疗公司	含磷的新的拟甲状腺素药
WO2005060647A2 (fr) *	2003-12-16	2005-07-07	Gtx, Inc.	Promedicaments de modulateurs selectifs des recepteurs aux androgenes et leurs methodes d'utilisation
US7514470B2 (en) *	2004-03-03	2009-04-07	Smithkline Beecham Corporation	Aniline derivatives as selective androgen receptor modulators
US8519158B2 (en)	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
CN1980891B (zh) *	2004-05-03	2011-03-09	詹森药业有限公司	作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物
MXPA06013115A (es) *	2004-05-11	2007-02-28	Pfizer Prod Inc	Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
PL1753417T3 (pl) *	2004-06-07	2012-09-28	Univ Tennessee Res Found	Selektywny modulator receptora androgenowego i jego zastosowania medyczne
CN102976973B (zh) *	2004-06-07	2015-10-21	田纳西大学研究基金会	选择性雄激素受体调节剂及其使用方法
US20110237664A1 (en) *	2004-06-07	2011-09-29	Dalton James T	Selective androgen receptor modulators for treating diabetes
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
MXPA06015169A (es) *	2004-07-08	2007-08-21	Warner Lambert Co	Moduladores de androgenos.
WO2007001448A2 (fr)	2004-11-04	2007-01-04	Massachusetts Institute Of Technology	Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques
CN101119993B (zh)	2005-01-10	2015-03-04	阿卡蒂亚药品公司	作为选择性雄激素受体调节剂的氨基苯基衍生物
US20060270641A1 (en) *	2005-05-31	2006-11-30	Steiner Mitchell S	Method for chemoprevention of prostate cancer
BRPI0609191B8 (pt) *	2005-06-17	2021-05-25	Ligand Pharm Inc	métodos e compostos moduladores de receptor de androgênio
JP2009506119A (ja) *	2005-08-31	2009-02-12	ユニバーシティオブテネシーリサーチファウンデーション	選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
WO2007045027A1 (fr)	2005-10-19	2007-04-26	Chavah Pty Ltd	Réduction des effets secondaires des inhibiteurs de l'aromatase employés dans le traitement du cancer du sein
US7790745B2 (en)	2005-10-21	2010-09-07	Bristol-Myers Squibb Company	Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US20090175845A1 (en) *	2005-10-25	2009-07-09	The Trustees Of Columbia University In The City Of New York	Methods for identifying compounds that modulate phb domain protein activity and compositions thereof
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
WO2007070682A2 (fr) *	2005-12-15	2007-06-21	Massachusetts Institute Of Technology	Systeme de criblage de particules
CA2648099C (fr)	2006-03-31	2012-05-29	The Brigham And Women's Hospital, Inc	Systeme pour l'administration ciblee d'agents therapeutiques
JP5630998B2 (ja)	2006-05-15	2014-11-26	マサチューセッツインスティテュートオブテクノロジー	機能的粒子のためのポリマー
WO2007150030A2 (fr)	2006-06-23	2007-12-27	Massachusetts Institute Of Technology	Synthèse microfluidique de nanoparticules organiques
US10010521B2 (en)	2006-08-24	2018-07-03	University Of Tennessee Research Foundation	SARMs and method of use thereof
US9844528B2 (en)	2006-08-24	2017-12-19	University Of Tennessee Research Foundation	SARMs and method of use thereof
US9730908B2 (en)	2006-08-24	2017-08-15	University Of Tennessee Research Foundation	SARMs and method of use thereof
ES2581765T3 (es) *	2006-08-24	2016-09-07	University Of Tennessee Research Foundation	Acilanilidas sustituidas y métodos de uso de las mismas
EA019849B1 (ru) *	2006-08-28	2014-06-30	Юниверсити Оф Теннесси Рисерч Фаундейшн	Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
EP2134830A2 (fr) *	2007-02-09	2009-12-23	Massachusetts Institute of Technology	Bioréacteur oscillant pour la culture de cellules
JP2010523595A (ja)	2007-04-04	2010-07-15	マサチューセッツインスティテュートオブテクノロジー	ポリ（アミノ酸）ターゲッティング部分
WO2008124634A1 (fr)	2007-04-04	2008-10-16	Massachusetts Institute Of Technology	Micelles inverses encapsulées par un polymère
CN101284795B (zh) *	2007-04-09	2012-04-25	中国科学院上海药物研究所	一类非甾体雄激素受体调节剂及其医学用途
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
CN103553966B (zh) *	2007-09-11	2016-09-07	Gtx公司	选择性雄激素受体调节剂的固体形态
EP2436376B1 (fr)	2007-09-28	2014-07-09	BIND Therapeutics, Inc.	Ciblage de cellules de cancer utilisant des nanoparticules
JP2011500569A (ja)	2007-10-12	2011-01-06	マサチューセッツインスティテュートオブテクノロジー	ワクチンナノテクノロジー
EP2222636B1 (fr)	2007-12-21	2013-04-10	Ligand Pharmaceuticals Inc.	Modulateurs sélectifs du récepteur androgène (sarm) et leurs utilisations
US8268872B2 (en)	2008-02-22	2012-09-18	Radius Health, Inc.	Selective androgen receptor modulators
CA2716320C (fr)	2008-02-22	2014-01-28	Radius Health, Inc.	Modulateurs selectifs du recepteur de l'androgene
JP2011519916A (ja) *	2008-07-02	2011-07-14	ファーマコステックカンパニーリミテッド	アミド誘導体の製造方法
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en)	2008-10-12	2013-01-01	The Brigham And Women's Hospital, Inc.	Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) *	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
WO2010093601A1 (fr)	2009-02-10	2010-08-19	Metabasis Therapeutics, Inc.	Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
AU2011212813B2 (en)	2010-02-04	2014-10-23	Radius Health, Inc.	Selective androgen receptor modulators
HUE030072T2 (en)	2010-05-12	2017-04-28	Radius Health Inc	Therapeutic prescriptions
US8642632B2 (en)	2010-07-02	2014-02-04	Radius Health, Inc.	Selective androgen receptor modulators
US9133182B2 (en)	2010-09-28	2015-09-15	Radius Health, Inc.	Selective androgen receptor modulators
US8395552B2 (en)	2010-11-23	2013-03-12	Metamagnetics, Inc.	Antenna module having reduced size, high gain, and increased power efficiency
KR102668696B1 (ko) *	2012-01-12	2024-05-29	예일 유니버시티	E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2834216A1 (fr)	2012-04-04	2015-02-11	Catylix Inc.	Modulateurs sélectifs de récepteur d'androgène
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
LT2872482T (lt)	2012-07-13	2020-12-28	Oncternal Therapeutics, Inc.	Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
RU2510392C1 (ru) *	2012-12-21	2014-03-27	Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН)	Сокристаллическая форма бикалутамида
US10441567B2 (en)	2014-01-17	2019-10-15	Ligand Pharmaceuticals Incorporated	Methods and compositions for modulating hormone levels
ES3055185T3 (en)	2014-03-28	2026-02-10	Univ Duke	Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9421264B2 (en)	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
AU2015331756A1 (en) *	2014-10-16	2017-05-04	Gtx, Inc.	Methods of treating urological disorders using SARMs
CA2965372C (fr)	2014-10-22	2023-09-05	Havah Therapeutics Pty Ltd	Procede de reduction de densite mammaire monographique et/ou de risque de cancer du sein
WO2016079522A1 (fr)	2014-11-20	2016-05-26	University College Cardiff Consultants Limited	Modulateurs du récepteur des androgènes et leur utilisation comme agents anticancéreux
WO2016079521A1 (fr)	2014-11-20	2016-05-26	University College Cardiff Consultants Limited	Modulateurs du récepteur des androgènes et leur utilisation comme agents anti-cancer
RU2724103C2 (ru)	2015-04-21	2020-06-22	Джи Ти Икс, ИНК.	Селективные лиганды-разрушители андрогенных рецептов (sard) и способы их применения
US10093613B2 (en)	2015-04-21	2018-10-09	Gtx, Inc.	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en)	2015-04-21	2017-12-05	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en)	2015-04-21	2018-07-31	Gtx, Inc.	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en)	2016-06-10	2020-05-19	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en)	2015-04-21	2020-12-15	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en)	2015-04-21	2020-10-20	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN107709290B (zh)	2015-04-21	2023-02-28	Gtx公司	选择性雄激素受体降解剂(sard)配体和其使用方法
US10441570B2 (en)	2015-04-21	2019-10-15	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10017471B2 (en)	2015-04-21	2018-07-10	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP2018534291A (ja)	2015-10-22	2018-11-22	ハバフセラピューティクスピーティーワイエルティーディー	マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法
US11230523B2 (en)	2016-06-10	2022-01-25	University Of Tennessee Research Foundation	Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX389702B (es)	2016-06-22	2025-03-20	Ellipses Pharma Ltd	Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
JP7481115B2 (ja)	2017-01-05	2024-05-10	ラジウスファーマシューティカルズ，インコーポレイテッド	Ｒａｄ１９０１－２ｈｃｌの多形性形態
JP2021523151A (ja)	2018-05-11	2021-09-02	ホスホレックス、インコーポレイテッド	負の表面電荷を有するマイクロ粒子及びナノ粒子
WO2020051344A1 (fr)	2018-09-05	2020-03-12	University Of Tennessee Research Foundation	Ligands de composés de dégradation sélectifs de récepteurs des androgènes (sard) et procédés d'utilisation associés
WO2020214834A1 (fr)	2019-04-19	2020-10-22	Ligand Pharmaceuticals Inc.	Formes cristallines et procédés de production de formes cristallines d'un composé
AU2020287392A1 (en)	2019-06-03	2021-12-23	Havah Therapeutics Pty Ltd	Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
KR20230084476A (ko)	2020-10-08	2023-06-13	타르그이뮨 테라퓨틱스 아게	암의 치료를 위한 면역요법
EP4001293A1 (fr) *	2020-11-23	2022-05-25	Justus-Liebig-Universität Gießen	Tétrapeptide et son utilisation
CN116801872A (zh) *	2021-02-10	2023-09-22	上海奕拓医药科技有限责任公司	调节雄激素受体凝聚物的方法
WO2023079142A2 (fr)	2021-11-05	2023-05-11	Targimmune Therapeutics Ag	Conjugués linéaires ciblés comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
US20260000700A1 (en)	2022-11-07	2026-01-01	Targimmune Therapeutics Ag	Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
IL320615A (en)	2022-11-07	2025-07-01	Targimmune Therapeutics Ag	PSMA-targeting linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same materials
IL320618A (en)	2022-11-07	2025-07-01	Targimmune Therapeutics Ag	Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
WO2025045058A1 (fr) *	2023-08-28	2025-03-06	中国药科大学	Composé agissant en tant qu'antagoniste du récepteur des androgènes
WO2025102293A1 (fr) *	2023-11-16	2025-05-22	北京脑科学与类脑研究所	Modulateur du récepteur des androgènes neuroactifs et son utilisation
WO2025238236A1 (fr)	2024-05-16	2025-11-20	Targimmune Therapeutics Ag	Polyplexes d'acides nucléiques et conjugués ciblés comprenant de la polyéthylèneimine et du polyéthylène glycol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3875229A (en)	1972-11-24	1975-04-01	Schering Corp	Substituted carboxanilides
US4139638A (en)	1976-09-23	1979-02-13	Schering Corporation	Methods for the treatment of hirsutism
EP0002309B1 (fr)	1977-10-12	1982-12-01	Imperial Chemical Industries Plc	Acylanilides, procédé pour leur préparation et compositions pharmaceutiques et vétérinaires les contenant
US4191775A (en)	1977-12-15	1980-03-04	Imperial Chemical Industries Limited	Amide derivatives
NZ197008A (en)	1980-05-22	1984-10-19	Ici Ltd	Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en)	1981-04-15	1982-10-22	Mitsubishi Petrochem Co Ltd	Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de)	1982-07-23	1987-08-15	Ici Plc	Amide-derivate.
GB8617652D0 (en)	1986-07-18	1986-08-28	Ici Plc	Acylanilide derivatives
GB8617653D0 (en) *	1986-07-18	1986-08-28	Ici Plc	Amide derivatives
US5162504A (en)	1988-06-03	1992-11-10	Cytogen Corporation	Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
AU1687395A (en)	1994-01-21	1995-08-08	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en)	1994-03-11	1997-03-11	The Trustees Of The University Of Pennsylvania	Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en)	1995-06-16	1997-08-12	Biophysica Inc.	Androgenic directed compositions
TW397821B (en) *	1996-04-19	2000-07-11	American Home Produits Corp	3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6071957A (en)	1996-11-27	2000-06-06	The University Of Tennessee Research Corporation	Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en)	1997-05-30	2000-12-12	The University Of Tennessee Research Corporation	Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (fr)	1997-06-04	1998-12-10	The University Of Tennessee Research Corporation	Composes agonistes/antagonistes non steroidiens radiomarques et leur utilisation dans la formation d'images du cancer de la prostate

2001
- 2001-08-23 DE DE60137728T patent/DE60137728D1/de not_active Expired - Lifetime
- 2001-08-23 MX MXPA03001632A patent/MXPA03001632A/es active IP Right Grant
- 2001-08-23 AU AU8523001A patent/AU8523001A/xx active Pending
- 2001-08-23 EP EP10182881A patent/EP2284149A1/fr not_active Withdrawn
- 2001-08-23 JP JP2002521186A patent/JP2004518617A/ja active Pending
- 2001-08-23 BR BR0114801-0A patent/BR0114801A/pt not_active IP Right Cessation
- 2001-08-23 EP EP01964368A patent/EP1401801B1/fr not_active Expired - Lifetime
- 2001-08-23 EP EP04019299A patent/EP1491524B1/fr not_active Expired - Lifetime
- 2001-08-23 ES ES04019299T patent/ES2321933T3/es not_active Expired - Lifetime
- 2001-08-23 EA EA200300283A patent/EA007101B1/ru not_active IP Right Cessation
- 2001-08-23 PT PT01964368T patent/PT1401801E/pt unknown
- 2001-08-23 GE GE5108A patent/GEP20053586B/en unknown
- 2001-08-23 CA CA2420279A patent/CA2420279C/fr not_active Expired - Lifetime
- 2001-08-23 AT AT01964368T patent/ATE344233T1/de active
- 2001-08-23 EP EP06014580A patent/EP1705174A1/fr not_active Withdrawn
- 2001-08-23 PT PT04019299T patent/PT1491524E/pt unknown
- 2001-08-23 EA EA200501269A patent/EA014224B1/ru not_active IP Right Cessation
- 2001-08-23 KR KR10-2003-7002652A patent/KR20030061783A/ko not_active Ceased
- 2001-08-23 CN CN2005100674946A patent/CN1736371B/zh not_active Expired - Fee Related
- 2001-08-23 AU AU2001285230A patent/AU2001285230C1/en not_active Ceased
- 2001-08-23 WO PCT/US2001/026328 patent/WO2002016310A1/fr not_active Ceased
- 2001-08-23 US US09/935,045 patent/US6569896B2/en not_active Expired - Fee Related
- 2001-08-23 SI SI200130685T patent/SI1401801T1/sl unknown
- 2001-08-23 AT AT04019299T patent/ATE423092T1/de active
- 2001-08-23 DK DK01964368T patent/DK1401801T3/da active
- 2001-08-23 CN CNB018178898A patent/CN1230418C/zh not_active Expired - Fee Related
- 2001-08-23 DK DK04019299T patent/DK1491524T3/da active
- 2001-08-23 ES ES01964368T patent/ES2275717T3/es not_active Expired - Lifetime
- 2001-08-23 DE DE60124322T patent/DE60124322T2/de not_active Expired - Lifetime
- 2001-08-23 HR HR20030118A patent/HRP20030118B1/xx not_active IP Right Cessation
2006
- 2006-05-29 JP JP2006147596A patent/JP2006306880A/ja active Pending
2007
- 2007-01-26 CY CY20071100104T patent/CY1105956T1/el unknown
2009
- 2009-05-08 CY CY20091100497T patent/CY1110459T1/el unknown

Also Published As

Publication number	Publication date
US20020099096A1 (en)	2002-07-25
US6569896B2 (en)	2003-05-27
DE60124322D1 (de)	2006-12-14
WO2002016310A9 (fr)	2002-07-18
WO2002016310A1 (fr)	2002-02-28
DE60137728D1 (de)	2009-04-02
HRP20030118A2 (en)	2005-02-28
ES2275717T3 (es)	2007-06-16
PT1401801E (pt)	2007-02-28
EP1491524A2 (fr)	2004-12-29
EP1401801A4 (fr)	2004-08-18
MXPA03001632A (es)	2004-09-10
EP2284149A1 (fr)	2011-02-16
EA014224B1 (ru)	2010-10-29
EP1705174A1 (fr)	2006-09-27
CN1736371B (zh)	2010-05-12
CA2420279C (fr)	2011-07-19
DK1491524T3 (da)	2009-05-04
EP1401801A1 (fr)	2004-03-31
ATE423092T1 (de)	2009-03-15
EA200501269A1 (ru)	2006-02-24
CN1471508A (zh)	2004-01-28
EP1491524A3 (fr)	2005-04-20
AU2001285230B2 (en)	2007-01-25
CY1110459T1 (el)	2015-04-29
JP2004518617A (ja)	2004-06-24
ES2321933T3 (es)	2009-06-15
HK1062011A1 (en)	2004-10-15
AU2001285230C1 (en)	2008-03-13
SI1401801T1 (sl)	2007-04-30
JP2006306880A (ja)	2006-11-09
KR20030061783A (ko)	2003-07-22
HK1072243A1 (en)	2005-08-19
BR0114801A (pt)	2003-10-14
CA2420279A1 (fr)	2002-02-28
EP1401801B1 (fr)	2006-11-02
EA200300283A1 (ru)	2003-08-28
EA007101B1 (ru)	2006-06-30
EP1491524B1 (fr)	2009-02-18
CN1230418C (zh)	2005-12-07
CY1105956T1 (el)	2011-04-06
PT1491524E (pt)	2009-04-16
DE60124322T2 (de)	2007-05-31
GEP20053586B (en)	2005-07-25
HRP20030118B1 (en)	2008-06-30
AU8523001A (en)	2002-03-04
CN1736371A (zh)	2006-02-22
ATE344233T1 (de)	2006-11-15

Publication	Publication Date	Title
DK1491524T3 (da)	2009-05-04	Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf
EA200000155A2 (ru)	2000-08-28	4-фенилпиридиновые производные
ES2149350T3 (es)	2000-11-01	Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion.
AU2002351753A8 (en)	2003-07-30	Combined use of a glp-1 compound and a modulator of diabetic late complications
JP2010143905A (ja)	2010-07-01	脂肪性物質およびジアミノピラゾロン誘導体を含む、ケラチン繊維の酸化染色のための組成物
PT721777E (pt)	2002-11-29	Utilizacao de tomoxetina para o tratamento do disturbio de deficit de atencao/hiperactividade
WO2003074450A3 (fr)	2004-08-05	Modulateurs selectifs radiomarques de recepteur d'androgene et leurs utilisations dans l'imagerie et la therapie du cancer de la prostate
CN106456491B (zh)	2020-01-10	用于使用氧化组合物和uv-可见辐射漂白或染色角蛋白纤维的方法
AR040644A1 (es)	2005-04-13	Un moduladores del receptor de progesterona benzoxazina-2-tiona, una composicion farmaceutica, uso del compuesto para preparar un dedicamento para tratar una enfermedad neoplasica-hormona-dependiente y el uso de un compuesto benzoxazina-2-tiona, benzoxazina-2-ilideno cianamida o benzoxazina-2-iliden
CO4950515A1 (es)	2000-09-01	Nuevos derivados de la quinolina para uso medicinal
IL126110A0 (en)	1999-05-09	Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use
BR0210873A (pt)	2004-06-22	Composição farmacêutica para terapia de cistite intersticial
FR2662714A1 (fr)	1991-12-06	Procede de teinture des fibres keratiniques avec le 2,4-diamino 1,3-dimethoxybenzene a ph acide et compositions mises en óoeuvre.
JPH0834715A (ja)	1996-02-06	パラ−フェニレンジアミン誘導体およびメタ−アミノフェノール誘導体を含有する、ケラチン繊維の酸化染色用組成物、および該組成物を用いる染色方法
GB2057019A (en)	1981-03-25	Process for dyeing human hair and composition for carrying out this process
AU1135395A (en)	1995-08-03	Phenyl-substituted alkylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or a diagnostic agent, and medicament containing them
FI945582A0 (fi)	1994-11-28	Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
KR890014458A (ko)	1989-10-23	치환된 히드라존 및 이들의 화합물을 함유하는 살균제
JP2530001B2 (ja)	1996-09-04	２，４−ジアミノ−１，３，５−トリメトキシンベンゼン、その製造方法および染毛組成物
ATE252896T1 (de)	2003-11-15	Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
SE9203211L (sv)	1993-05-02	Tygmjukningsmedel med fettsyra och slaeppmedel
EE03214B1 (et)	1999-08-16	Fenüületüül- ja fenüülpropüülamiinid, nende valmistamise protsessid ja neid sisaldavad ravimpreparaadid
WO2012177558A2 (fr)	2012-12-27	Composition de colorant capillaire et procédé pour la coloration de cheveux l'utilisant
KR960703844A (ko)	1996-08-31	디플루오로 스타톤 동족체(Difluoro statone analogs)
DK1011672T3 (da)	2006-02-06	Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger